PURPOSE: To determine whether concurrent androgen deprivation therapy (ADT) during salvage radiotherapy (RT) improves prostate cancer treatment outcomes. METHODS AND MATERIALS: A total of 630 postprostatectomy patients were retrospectively identified who were treated with three-dimensional conformal RT. Of these, 441 were found to be treated for salvage indications. Biochemical failure was defined as prostate-specific antigen (PSA) of 0.2 ng/mL or greater above nadir with another PSA increase or the initiation of salvage ADT. Progression-free survival (PFS) was defined as the absence of biochemical failure, continued PSA rise despite salvage therapy, initiation of systemic therapy, clinical progression, or distant failure. Multivariate-adjusted Cox proportional hazards modeling was performed to determine which factors predict PFS. RESULTS: Low-, intermediate-, and high-risk patients made up 10%, 24%, and 66% of patients, respectively. The mean RT dose was 68 Gy. Twenty-four percent of patients received concurrent ADT (cADT). Regional pelvic nodes were treated in 16% of patients. With a median follow-up of 3 years, the 3-year PFS was 4.0 years for cADT vs. 3.4 years for cADT patients (p = 0.22). Multivariate analysis showed that concurrent ADT (p = 0.05), Gleason score (p < 0.001), and pre-RT PSA (p = 0.03) were independent predictors of PFS. When patients were stratified by risk group, the benefits of cADT (hazard ratio, 0.65; p = 0.046) were significant only for high-risk patients. CONCLUSIONS: This retrospective study showed a PFS benefit of concurrent ADT during salvage prostate RT. This benefit was observed only in high-risk patients.
PURPOSE: To determine whether concurrent androgen deprivation therapy (ADT) during salvage radiotherapy (RT) improves prostate cancer treatment outcomes. METHODS AND MATERIALS: A total of 630 postprostatectomy patients were retrospectively identified who were treated with three-dimensional conformal RT. Of these, 441 were found to be treated for salvage indications. Biochemical failure was defined as prostate-specific antigen (PSA) of 0.2 ng/mL or greater above nadir with another PSA increase or the initiation of salvage ADT. Progression-free survival (PFS) was defined as the absence of biochemical failure, continued PSA rise despite salvage therapy, initiation of systemic therapy, clinical progression, or distant failure. Multivariate-adjusted Cox proportional hazards modeling was performed to determine which factors predict PFS. RESULTS: Low-, intermediate-, and high-risk patients made up 10%, 24%, and 66% of patients, respectively. The mean RT dose was 68 Gy. Twenty-four percent of patients received concurrent ADT (cADT). Regional pelvic nodes were treated in 16% of patients. With a median follow-up of 3 years, the 3-year PFS was 4.0 years for cADT vs. 3.4 years for cADTpatients (p = 0.22). Multivariate analysis showed that concurrent ADT (p = 0.05), Gleason score (p < 0.001), and pre-RT PSA (p = 0.03) were independent predictors of PFS. When patients were stratified by risk group, the benefits of cADT (hazard ratio, 0.65; p = 0.046) were significant only for high-risk patients. CONCLUSIONS: This retrospective study showed a PFS benefit of concurrent ADT during salvage prostate RT. This benefit was observed only in high-risk patients.
Authors: Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin Journal: JAMA Date: 2005-07-27 Impact factor: 56.272
Authors: Andrew J Stephenson; Peter T Scardino; Michael W Kattan; Thomas M Pisansky; Kevin M Slawin; Eric A Klein; Mitchell S Anscher; Jeff M Michalski; Howard M Sandler; Daniel W Lin; Jeffrey D Forman; Michael J Zelefsky; Larry L Kestin; Claus G Roehrborn; Charles N Catton; Theodore L DeWeese; Stanley L Liauw; Richard K Valicenti; Deborah A Kuban; Alan Pollack Journal: J Clin Oncol Date: 2007-05-20 Impact factor: 44.544
Authors: J A Freeman; G Lieskovsky; G Grossfeld; D Esrig; J P Stein; D W Cook; Z Petrovich; S C Chen; S Groshen; D G Skinner Journal: Urology Date: 1994-11 Impact factor: 2.649
Authors: Alex Z Fu; Huei-Ting Tsai; Reina Haque; Marianne Ulcickas Yood; Andrea E Cassidy-Bushrow; Stephen K Van Den Eeden; Nancy L Keating; Matthew R Smith; Yingjun Zhou; David S Aaronson; Arnold L Potosky Journal: J Urol Date: 2016-12-19 Impact factor: 7.450
Authors: Alex Z Fu; Huei-Ting Tsai; Reina Haque; Marianne Ulcickas Yood; Stephen K Van Den Eeden; Andrea E Cassidy-Bushrow; Yingjun Zhou; Nancy L Keating; Matthew R Smith; David S Aaronson; Arnold L Potosky Journal: World J Urol Date: 2016-04-15 Impact factor: 4.226
Authors: Pirus Ghadjar; Daniel M Aebersold; Clemens Albrecht; Dirk Böhmer; Michael Flentje; Ute Ganswindt; Stefan Höcht; Tobias Hölscher; Felix Sedlmayer; Frederik Wenz; Daniel Zips; Thomas Wiegel Journal: Strahlenther Onkol Date: 2018-01-30 Impact factor: 3.621
Authors: Ohseong Kwon; Ki Bom Kim; Young Ik Lee; Seok-Soo Byun; Jae-Sung Kim; Sang Eun Lee; Sung Kyu Hong Journal: PLoS One Date: 2014-07-29 Impact factor: 3.240